Key Highlights
- Net loss was USD 2.55 million, compared with USD 1.87 million.
- Loss per share was USD 0.57, compared with USD 10.81.
- Research and development expenses were USD 1.35 million, compared with USD 402 thousand.
- Cash was USD 5.61 million at September 30, 2026.
Enveric Biosciences (NASDAQ:ENVB) reported a net loss of USD 2.55 million for the third quarter of 2026, compared with USD 1.87 million in the prior-year quarter. Net loss per share, basic and diluted, was USD 0.57, compared with USD 10.81.
For the nine months ended September 30, 2026, the net loss was USD 7.21 million, compared with USD 6.58 million, and net loss per share was USD 2.17, compared with USD 35.74.
Operating Expenses
Research and development expenses were USD 1.35 million, compared with USD 402 thousand. General and administrative expenses were USD 1.17 million, compared with USD 1.43 million, and Depreciation and amortization was USD 35 thousand, compared with USD 40 thousand.
Total operating expenses were USD 2.56 million, compared with USD 1.87 million, and loss from operations was USD 2.56 million, compared with USD 1.87 million. Weighted average shares outstanding, basic and diluted, were 4,483,762, compared with 313,242.
Nine-Month Results
For the nine months, Research and Development expenses were USD 3.06 million, compared with USD 2.41 million, and general and administrative expenses were USD 4.06 million, compared with USD 4.01 million. Total operating expenses were USD 7.22 million, compared with USD 6.58 million.
The prior-year periods included a deemed Dividend on the inducement of warrants of USD 1.51 million. Weighted average shares outstanding for the nine months were 3,330,286, compared with 226,400.
Cash and Liquidity
Cash was USD 5.61 million at September 30, 2026, compared with USD 4.68 million at December 31, 2025. The filing states that the increase was primarily a result of proceeds received from the April 2026 private Placement and Warrant exercises, partially offset by cash used in operating activities.
Total Assets were USD 6.37 million, compared with USD 5.10 million. The filing states that certain factors raise substantial doubt about the company's ability to continue as a Going Concern for a period of one year from the issuance of the financial statements.
The filing states that the company's primary focus is to develop its lead asset EB-003 in the EVM301 Series, which has been advanced into formal preclinical development studies in support of a future Investigational New Drug filing. In the fourth quarter of 2024, the company out-licensed the EVM201 Series program to MycoMedica Life Sciences in exchange for certain development and milestone payments, and on February 25, 2025 it unveiled the EVM401 Series.
The filing states that the Series G warrants expire five years following the effective date of the resale registration statement and that the Series H warrants expire 18 months following that date.
Other income was USD 15 thousand for the quarter and the nine months, compared with nil for the prior-year quarter and USD 2.6 thousand for the prior-year nine months. Income tax expense was nil in each period presented.
Enveric Biosciences Q3 2026 Earnings: Key Takeaways
Enveric Biosciences reported a third quarter 2026 net loss of USD 2.55 million and a loss per share of USD 0.57. Cash was USD 5.61 million at September 30, 2026.






Please wait processing your request...